Shucai Zhang

TL;DR: It is suggested that erlotinib is important for first-line treatment of patients with advanced EGFR mutation-positive NSCLC, and was associated with more favourable tolerability than standard chemotherapy.

TL;DR: The significant OS benefit observed in patients treated with EGFR-TKI emphasises its contribution to improving survival of EGFR mutation-positive advanced non-small-cell lung cancer patients, suggesting that erlotinib should be considered standard first-line treatment of EGfr mutant patients and EGFR -TKI treatment following first- line therapy also brings significant benefits to those patients.

TL;DR: Icotinib was non-inferior to gefitinib in terms of progression-free survival and could be a new treatment option for pretreated patients with advanced non-small-cell lung cancer.

TL;DR: Investigating the efficacy, safety, and tolerability of the EGFR-tyrosine-kinase inhibitor gefitinib in the maintenance setting found it significantly prolonged progression-free survival compared with placebo in patients from east Asia who achieved disease control after first-line chemotherapy.

TL;DR: The relatively high frequency of EGFR mutations in the mainland China subset suggest that any effort to obtain tissue sample for EGFR mutation testing should be encouraged, and is independently associated with the intensity of tobacco use and regional lymph nodes involvement.